Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04650191 · ClinicalTrials.gov registry record
Surfactant Protein Genetic Variants in COVID-19 Infection
A clinical trial, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- 300
- Enrollment target
NCT04650191 is a clinical trial that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 300 participants.
The verdict
NCT04650191 has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
Surfactant protein plays important role in innate immunity against respiratory viral infections. However, investigators have shown that the surfactant protein polymorphisms are associated with severity of various pulmonary diseases such as respiratory syncytial virus (RSV), tuberculosis, pediatric acute lung injury. COVID-19 virus gains entry through the respiratory system and responsible for death due to acute respiratory failure. There is a considerable heterogeneity in presentation of COVID-19 infection from asymptomatic patients to severe infection requiring intensive care and some may die. Considering reports of COVID-19 related deaths/severe disease in the same family, it is possible that genetics play an important role in severity of COVID-19 infection. Investigators propose to study the association of surfactant proteins in COVID-19 patients. Key Objectives: a) Characterize genetic markers within the surfactant protein genes in COVID-19 positive patients, b) To determine if there is a correlation between certain genetic markers and the severity of COVID-19 infection which may be used as a prognostic marker, c) To correlate genetic markers with immune studies.
Interventions
- OTHER Identification of genetic variants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2022-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04650191
The ClinicalTrials.gov registry entry for NCT04650191 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Identification of genetic variants is the first listed.
NCT04650191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04650191 about?
NCT04650191 is a clinical study titled "Surfactant Protein Genetic Variants in COVID-19 Infection". Surfactant protein plays important role in innate immunity against respiratory viral infections. However, investigators have shown that the surfactant protein polymorphisms are associated with severity of various pulmonary diseases such as respiratory syncytial virus (RSV), tuberculosis, pediatric a...
What is the current status of trial NCT04650191?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2020-03-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04650191?
The interventions under investigation include: Identification of genetic variants (OTHER).
Who is sponsoring clinical trial NCT04650191?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.